Stroke:年轻人缺血性卒中后他汀类药物使用与长期结局的关系

2019-11-09 xing.T MedSci原创

由此可见,年轻的缺血性卒中患者中有不到一半使用他汀类药物,其使用受年龄和危险因素的影响。服用他汀类药物与降低全因死亡率和卒中复发的风险独立相关。

年轻人对于卒中二级预防药物的认识十分有限。近日,心血管疾病领域权威杂志Stroke上发表了一篇研究文章,研究人员旨在探究他汀类药物的使用情况及其与缺血性卒中的年轻成年人(已知动脉粥样硬化负担低的患者组)随后血管事件之间的相关性。

研究人群来自1994年至2007年期间赫尔辛基年轻卒中登记中心的935名15至30岁在30天内首次的缺血性中风幸存者。随访数据来自芬兰社会保险机构(药物处方登记中心)、芬兰护理登记中心和芬兰统计局,截至2012年。研究人员通过调整的Cox回归分析评估了他汀类药物的使用(定义为至少购买2次)与全因死亡率、复发性卒中和其他复发性血管事件之间的相关性。研究人员进一步比较了匹配的他汀类药物使用者和未使用者倾向评分。

在935例患者中,随访期间有46.8%的人使用他汀类药物。高龄、血脂异常、大量饮酒和高血压与购买他汀类药物显著相关。调整血脂异常、卒中亚型和其他混杂因素后,他汀类药物使用者的全因死亡率(风险比为0.38[95%CI为0.25-0.58])和卒中复发(风险比为0.29[95%CI为0.19-0.44])风险较低。倾向评分-匹配比较后,这些结果保持不变。

由此可见,年轻的缺血性卒中患者中有不到一半使用他汀类药物,其使用受年龄和危险因素的影响。服用他汀类药物与降低全因死亡率和卒中复发的风险独立相关。 

原始出处:

Myrna Marita Elisabeth van Dongen.et al.Use of Statins After Ischemic Stroke in Young Adults and Its Association With Long-Term Outcome.stroke.2019.https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.026992

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1971587, encodeId=628f19e1587b1, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Feb 10 20:34:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044566, encodeId=8b902044566c0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Apr 19 18:34:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671385, encodeId=1ef616e13856e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Feb 08 14:34:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806358, encodeId=9fbe18063584d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Dec 30 10:34:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893231, encodeId=ccdf189323191, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 02 17:34:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385113, encodeId=05521385113b5, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Mon Nov 11 04:34:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026494, encodeId=5f3a102649474, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 09 16:34:00 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1971587, encodeId=628f19e1587b1, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Feb 10 20:34:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044566, encodeId=8b902044566c0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Apr 19 18:34:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671385, encodeId=1ef616e13856e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Feb 08 14:34:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806358, encodeId=9fbe18063584d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Dec 30 10:34:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893231, encodeId=ccdf189323191, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 02 17:34:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385113, encodeId=05521385113b5, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Mon Nov 11 04:34:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026494, encodeId=5f3a102649474, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 09 16:34:00 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1971587, encodeId=628f19e1587b1, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Feb 10 20:34:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044566, encodeId=8b902044566c0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Apr 19 18:34:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671385, encodeId=1ef616e13856e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Feb 08 14:34:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806358, encodeId=9fbe18063584d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Dec 30 10:34:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893231, encodeId=ccdf189323191, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 02 17:34:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385113, encodeId=05521385113b5, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Mon Nov 11 04:34:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026494, encodeId=5f3a102649474, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 09 16:34:00 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1971587, encodeId=628f19e1587b1, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Feb 10 20:34:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044566, encodeId=8b902044566c0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Apr 19 18:34:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671385, encodeId=1ef616e13856e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Feb 08 14:34:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806358, encodeId=9fbe18063584d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Dec 30 10:34:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893231, encodeId=ccdf189323191, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 02 17:34:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385113, encodeId=05521385113b5, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Mon Nov 11 04:34:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026494, encodeId=5f3a102649474, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 09 16:34:00 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1971587, encodeId=628f19e1587b1, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Feb 10 20:34:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044566, encodeId=8b902044566c0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Apr 19 18:34:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671385, encodeId=1ef616e13856e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Feb 08 14:34:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806358, encodeId=9fbe18063584d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Dec 30 10:34:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893231, encodeId=ccdf189323191, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 02 17:34:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385113, encodeId=05521385113b5, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Mon Nov 11 04:34:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026494, encodeId=5f3a102649474, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 09 16:34:00 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1971587, encodeId=628f19e1587b1, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Feb 10 20:34:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044566, encodeId=8b902044566c0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Apr 19 18:34:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671385, encodeId=1ef616e13856e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Feb 08 14:34:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806358, encodeId=9fbe18063584d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Dec 30 10:34:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893231, encodeId=ccdf189323191, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 02 17:34:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385113, encodeId=05521385113b5, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Mon Nov 11 04:34:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026494, encodeId=5f3a102649474, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 09 16:34:00 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1971587, encodeId=628f19e1587b1, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Feb 10 20:34:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044566, encodeId=8b902044566c0, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Apr 19 18:34:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671385, encodeId=1ef616e13856e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sat Feb 08 14:34:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806358, encodeId=9fbe18063584d, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Dec 30 10:34:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893231, encodeId=ccdf189323191, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 02 17:34:00 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385113, encodeId=05521385113b5, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Mon Nov 11 04:34:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026494, encodeId=5f3a102649474, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 09 16:34:00 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
    2019-11-09 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

相关资讯

Neurology:根据年龄、亚型、性别的年轻人卒中发病率和时间趋势

由此可见,35岁以上的中年人卒中发病率随年龄增长而增加,18-44岁人群中,女性高于男性,在十年内增加了23%,并且是缺血性卒中增加为主。女性和男性的脑内出血发病率相当,并且随着时间的推移保持稳定。

JACC:年轻HFpEF患者更常见于肥胖男性,且猝死率高

虽然,射血分数保留的心力衰竭(HFpEF)被认为是老年人的疾病,但年轻患者也可出现这种综合症。JACC发表的一项研究探讨了HFpEF患者的年龄、临床特征和预后的关系。

越来越多的年轻人死于结肠癌

2019年6月7日 - 当34岁的Heather Blackburn-Beel第一次出现胃痛时,印第安纳州居民,两个孩子的母亲和全职护士认为这是一种肠易激综合征,加上她忙碌而紧张的日程安排。

Sci Rep:41%年轻人后脑勺长“刺”,或因长时间低头看手机

近期,澳大利亚学者对1200张成年人X线片进行的分析发现,很多人由于经常低着脑袋看手机,后脑勺变了:一个叫枕外隆突的部位长出来一根“刺”。

Gut:欧洲年轻人中结直肠癌的发病率增加

由此可见,欧洲年轻人CRC发病率上升,但这一趋势的原因需要进一步阐明。临床医生应该意识到这种趋势。如果趋势继续下去,可能需要重新考虑筛查指南。

Circulation:肥胖可能是年轻人HFpEF发病率高的主要驱动因素

射血分数保留的心力衰竭(HFpEF),传统上被认为是老年疾病,但也可影响年轻患者。然而,对年轻人的HFpEF知之甚少。Circulation发表的一项最新研究对这一问题进行了探讨。